Repurposing NASVAC, a hepatitis B therapeutic vaccine, for pre- and postexposure prophylaxis of SARS-CoV-2 infection

Abstract excerpt

<title>Abstract</title> <p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus 2019 (COVID-19) have led to tens of millions of cases and millions of deaths around the world. Although more than a year has passed since the emergence of COVID-19, more waves of the pandemic, with new variants of the deadly virus, have been reported. It seems that the virus will continue to infe...

Topics

Open a Topic to create a Post that cites this publication.

• COVID-19 Clinical Research Studies
• Drug Design
• Drug Evaluation, Preclinical
• Hepatitis C Antibodies
• Hepatocytes
• Immunogenicity, Vaccine
• SARS-CoV-2 and COVID-19 Research
• Vaccines, DNA

Identifiers and source

Literature Corpus work

58649101-66bd-5228-8dd4-68bdae26cf29

DOI

10.21203/rs.3.rs-438628/v1